Healthcare Nanotechnology (Nanomedicine) Market Size, Share & Trends Analysis Report By Applications (Drug Delivery, Biomaterials, Active Implants, Diagnostic Imaging, Tissue Regeneration), By Disease (Cardiovascular Diseases, Oncological Diseases, Neurological Diseases, Orthopedic Diseases, Infectious Diseases, Other Diseases) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Overview

The global healthcare nanotechnology (nanomedicine) market size was valued at USD 224.90 billion in 2022. It is projected to reach USD 389.42 billion by 2031, growing at a CAGR of 16.1% during the forecast period (2023-2031). 

Cancer, Parkinson's disease, Alzheimer's disease, diabetes, orthopedic illnesses, and diseases of the blood, lungs, and cardiovascular system are just a few of the life-threatening illnesses that can be treated with nanomedicine. Several factors, including the rising incidence of cancer and genetic and cardiovascular diseases, the advancement of nanoscale technologies for diagnostic procedures, and the increasing demand for personalized medicines, are currently propelling the growth of the global  market. Due to the high prevalence of dementia, there will likely be a rise in the need for effective nanomedicine-based therapies to control the condition, propelling market expansion.

Market Dynamics

Market drivers

Growing Prevalence of Cancer and Genetic and Cardiovascular Diseases

Several factors, including the rising incidence of cancer and genetic and cardiovascular diseases, the advancement of nanoscale technologies for diagnostic procedures, and the increasing demand for personalized medicines, are currently propelling the growth of the global healthcare nanotechnology (nanomedicine) market. Cancer, Parkinson's disease, Alzheimer's disease, diabetes, orthopedic illnesses, and diseases of the blood, lungs, and cardiovascular system are just a few of the life-threatening illnesses that can be treated with nanomedicine.

Alzheimer's Disease International estimates that 50 million people will have dementia worldwide in 2020. Every 20 years, this population is anticipated to double, rising to 81 million in 2030 and 150 million in 2050. Due to the high prevalence of dementia, there will likely be a rise in the need for effective nanomedicine-based therapies to control the condition, propelling market expansion.

Market restraint

Stringent Regulations for Commercial Introduction

Applications of nanotechnology in the pharmaceutical sector will need to meet strict requirements for environmental, public health, and safety protection. The market's expansion is anticipated to be hampered by strict rules assessing nanoparticles' health, environmental, and adverse effects. Several nations currently have varied regulatory standards for approving new products. A single regulatory procedure is used for the marketing authorization application (MAA), and pre-marketing clinical trials are frequently conducted in three phases. The FDA has the right to ask for more study-related information at any point in the clinical studies or to halt them altogether if there are any safety or efficacy-related worries. Additionally, the FDA may stop a clinical study if the results from a trial are deemed dangerous.

Market opportunities

Increasing Advancements in Nanoscale Technologies for Diagnostic Procedures

Tools based on nanotechnology have begun to catch the interest of researchers across the globe. Rapid diagnostic tests based on nanotechnology are now being developed using a variety of nanomaterials, including magnetic nanoparticles, metallic nanoparticles, carbon nanotubes, nanostructured surfaces, quantum dots, silicon nanowires, nanopores, graphene, and metal films. Multifunctional nanosized sensors have been developed to detect many disease factors, such as foreign proteins/antigens and harmful chemicals. For instance, new bio-barcodes were created to target protein disease markers, including prostate-specific antigens, according to a study by Amr El-Sayed et al., published in Environmental Science and Pollution Research Journal in 2019. (PSA). Based on anti-PSA antibodies, these biosensors can detect prostate cancer at an incredibly early stage.

Rising Preference for Personalized Medicines

Nanotechnologies have a significant global impact on medicine, particularly on the study and treatment of cancer. Researchers now have renewed hope that they may be able to treat cancer by using drug delivery systems based on liposomes, metal nanoparticles, quantum dots, magnetic nanoparticles, polymeric nanoparticles, or carbon nanomaterials. However, it is challenging to diagnose diseases like cancer, Alzheimer's disease (AD), and HIV at an early stage due to the intricacy of the illness and the variations from person to person. Personalized medicine, tailoring or monitoring diagnoses and therapy to an individual's genetic profile, has been introduced to address such problems.

The development of cancer nanotechnology for personalized oncology uses genetic and protein biomarkers to treat cancer. Gold nanoparticles are studied in cancer therapy, medication transport, and in vitro and in vivo imaging. Gold nanoparticles with oligonucleotide caps have been used to detect proteins like p53 using the atomic force microscope (AFM), SPR imaging, Raman spectroscopy, and econometric assay.

Regional Analysis

North america dominates the global market

The global market is bifurcated into four regions: North America, Europe, Asia-Pacific, and LAMEA. 

North America is the most significant revenue contributor and is expected to exhibit a CAGR of 11.70% during the forecast period. Technology developments and related applications in early illness detection, preventative intervention, and prevention of chronic and acute disorders are the main factors contributing to the growth, which are predicted to support market expansion in the United States. One in seven fatalities in the United States is caused by heart disease, according to the American Heart Association Research Report 2018. The most significant cause of mortality from cardiovascular disease in the United States in 2018 was coronary heart disease (43.8%), which was followed by stroke (16.8%), heart failure (9.0%), high blood pressure (9.4%), disorders of the arteries (3.1%), and other cardiovascular illnesses (17.9%). Specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration will be in great demand.

Europe is expected to exhibit a CAGR of 12.30% during the forecast period. Due to reasons like expanding collaborations between operating businesses and start-up organizations for nanomedicine, the French market is increasing. Additionally, a large portion of the region's participation in the industrial space can be attributed to government backing and increased R&D spending. Further, the expansion of the regional market is boosted by an increase in research funds and the need for prevention against fatal diseases. One in three French persons in 2019 had significant cardiovascular disease risk factors, according to the Fondation de France. Therefore, the market under study is anticipated to expand significantly in France throughout the forecast period due to high-end R&D initiatives, new product launches, and rising target disease prevalence.

One nation that made significant investments in the field of nanotechnology was China. The first investment was relatively modest. However, many nations, particularly China, significantly increased their nanotechnology financing. According to a 2016 study titled "Nanotechnology Development in China: challenges and opportunities," the National Natural Science Foundation of China supported three significant programs in nanoscience, nanomanufacturing, and molecular assembly with a budget of CNY 200 million each. It also funded several basic projects in all areas of nano research. Additionally, through several programs like the Innovation Programs and Innovation 2020, the Chinese Academy of Sciences (CAS) in Beijing has been promoting nanotechnology research.

Brazil has a friendly government and a populace that is expanding. The nation has experienced a significant change in the private health sector, which is an encouraging sign for the nanotechnology market. Over the anticipated period, it is anticipated that the Brazilian market will experience significant expansion. The main factors driving the expansion of the regional market are the rising prevalence of chronic disorders, the growing elderly population base, which is more susceptible to several target ailments, and rising awareness. Among other nations, the rest of South America includes Colombia, Bolivia, Chile, Ecuador, Guyana, Paraguay, and Peru. These are primarily developing nations with healthcare spending substantially lower overall than that of Argentina or Brazil. Countries like Colombia and Peru have similar economic situations because their per capita incomes are comparable.

Segmental Analysis

The global healthcare nanotechnology (nanomedicine) in the healthcare industry is segmented by application and disease.

Based on application, global healthcare nanotechnology (nanomedicine) in pharmaceutical industry is bifurcated into drug delivery, biomaterials, active implants, diagnostic imaging, and tissue regeneration.

The drug delivery segment is the highest contributor to the market and is estimated to exhibit a CAGR of 10.80% during the forecast period. The first step in using nanomaterials for drug administration is choosing the nanoparticle, which is mainly determined by the physicochemical properties of the medication. Nanotechnology and bioactive natural chemicals are being used together more and more frequently. Medical devices and pharmaceuticals frequently use nanoscale technologies to manipulate molecules at the molecular level to use a material's unique features. Improving the delivery of therapies and healthcare outcomes is the primary demand in this area of medicine. A promising method of treating cancer is nanomedicine. Better-tailored treatments for various diseases, including cancer, can be found using this expanding area of medical study.

Living tissue and synthetic materials that can be utilized to restore, replace, and stimulate biological systems are referred to as biomaterials. Numerous industries use biomaterials, including the orthopedic, dentistry, cardiovascular, ophthalmology, and wound healing industries. Nanobiotechnology, a rapidly expanding discipline, combines molecular assembly and nanoscale design to give control over biological processes. These biomaterials are also utilized in the medical field to enhance human health. By altering the biomaterial's composition, the nanoscale biomaterial can rebuild and regulate the blood-brain barrier (BBB) and restore the central nervous system's (CNS) equilibrium.

Dental implant surfaces are increasingly being modified using nanotechnology. Brain implants are also frequently used to treat epilepsy, Parkinson's disease, and depression. They can support scientific and medical studies by facilitating drug administration and restoring motion and communication in persons with neurodegenerative illnesses. The benefits of using nanotechnology in brain implants have created many possibilities. Additionally, acellular synthetic polymeric brain implants that distribute medications to the central nervous system can be made using nanotechnology.

Nanomaterials are widely employed in cancer treatment and biomedical imaging, including nanoparticles, nanospheres, nanorods, nanoshells, and nanostars. Diagnostic and medical imaging fields have seen significant transformations since the development of nanotechnology. Several applications related to silica nanoparticles, quantum dots, gold nanoparticles, and other nanoparticles have improved the performance potential of the currently available diagnostic instruments. Liposomes, lipoproteins, and carbon nanotubes are gadolinium complexes that can be used as imaging contrast agents. They can also be used as contrast in MRI, which may produce positive differences based on agent accumulation in the tissue.

Based on disease, the global market is bifurcated into cardiovascular, oncological, neurological, orthopedic, infectious, and other diseases.

The oncological diseases segment is the major contributor to the market and is estimated to grow at a CAGR of 13.80% during the forecast period. The main factors influencing the growth of the market under study are the growing incidence rates of cancer around the world, technological advancements in oncology nanomedicines, and an increase in the number of product approvals. Vyxeos, a 44 mg/100 mg powder for infusion for treating people with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplastic alterations, received clearance from the European Commission in August 2018. (AML-MRC). As a result, throughout the projection period, leading companies in the field of cancer nanomedicine are predicted to make a wide variety of investments, expand research and development activities, and have high product approval rates.

Nanotechnology has wholly changed how neurological disorders are treated, and it can potentially treat neurodegenerative diseases like Alzheimer's, Parkinson's, stroke, epilepsy, Huntington's, and multiple sclerosis. The Alzheimer's Association's Alzheimer's Disease Facts and Figures 2020 report estimates that 5.8 million Americans age 65 and older had Alzheimer's dementia in 2020. By 2050, this figure is expected to go up to 14 million. By June 2021, Aphios plans to begin a clinical trial to examine the efficacy, safety, and safety of intranasal nanoparticles of APH-1105, an alpha-secretase modulator for mild to moderate cognitive impairment brought on by Alzheimer's disease (AD).

Numerous novel therapies in the area of orthopedics have been made possible by the expanding use of nanotechnology in medicine, including targeted medication delivery, implantable materials, spinal disc degeneration, and diagnostic modalities. The rising research efforts and product launch significantly influence the expansion of the researched segment. 

Asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD) have benefited from using nanomedicine in treatment. The most effective method for treating various lung disorders is the local delivery of therapeutic nanoparticles to the lungs. The targeted drug delivery by inhalation enables the anti-asthma medications to enter the lungs directly, eliminating the first-pass impact and enhancing bioavailability, according to the research article published in Annals of Translational Medicine, 2019. According to a study published in Nanoengineered Biomaterials for Advanced Drug Delivery in 2020, using nanoparticles made with bioadhesive polymers promotes the local concentration of fluoride in the dental hard tissues while avoiding rapid salivary clearance and excessive consumption of the mineral, thereby reducing systemic effects.

Recent Developments

• January 2022- To create a NaNot that targets the soluble form of the immunological inhibitor PD-L1, produced by tumors, NaNotics LLC and the Mayo Clinic initiated a research partnership.
• March 2021- For the developments in the European medical nanotechnology sector, a partnership between two Barcelona institutions and the University of Manchester's Nanomedicine Lab obtained financing totaling EUR 12 million.